Cosio F G, Frankel W L, Pelletier R P, Pesavento T E, Henry M L, Ferguson R M
Department of Internal Medicine, The Ohio State University, Columbus, OH 43210-1228, USA.
Am J Kidney Dis. 1999 Oct;34(4):731-8. doi: 10.1016/S0272-6386(99)70400-2.
De novo focal segmental glomerulosclerosis (FSGS) in renal allografts most often is diagnosed in association with chronic allograft nephropathy (CN). In this study, we assessed the clinical and pathological variables that correlate with the presence of de novo FSGS and the implications of FSGS for the survival of grafts with CN. The study population included 293 renal allograft recipients (52 living related donor, 241 cadaveric donor) diagnosed with CN by biopsy more than 6 months after transplantation. Patients with recurrent FSGS or FSGS associated with other glomerulopathies were excluded. FSGS was present in 87 patients with CN (30%). FSGS was diagnosed more commonly in the following groups of patients: young (P = 0.04), black (P = 0.02), and those with elevated serum cholesterol levels (P = 0.002) and/or high-grade proteinuria (P < 0. 0001, all univariate analysis). FSGS was diagnosed later after transplantation than CN without FSGS (P < 0.0001), and FSGS correlated with the presence of arteriolar hyalinosis in the biopsy specimen (P = 0.04). Compared with CN without FSGS, FSGS was associated with significantly worse death-censored graft survival (P = 0.008, univariate Cox). In addition, when we analyzed all patients with CN, graft survival correlated by multivariate analysis with the following parameters: serum creatinine level (P < 0.0001) and proteinuria (P = 0.004) at the time of diagnosis, presence of FSGS (P = 0.03), and degree of interstitial fibrosis and tubular atrophy (CN score; P < 0.0001, Cox). Of interest, the use of lipid-reducing agents was also associated with improved graft survival in patients with CN (P = 0.0002, univariate Cox), although total lipid levels were not significantly less in patients receiving these drugs. In conclusion, de novo FSGS presents late after transplantation and in association with arteriolar hyalinosis, suggesting these lesions may be related to chronic cyclosporine toxicity. In CN, the presence of FSGS and the severity of interstitial fibrosis are negative independent predictors of graft survival. The possible relationship between lipid-reducing agents and graft survival clearly needs to be examined carefully in future studies.
肾移植中新生的局灶节段性肾小球硬化(FSGS)最常与慢性移植肾肾病(CN)相关联而被诊断出来。在本研究中,我们评估了与新生FSGS的存在相关的临床和病理变量,以及FSGS对患有CN的移植肾存活的影响。研究人群包括293名肾移植受者(52名活体亲属供肾,241名尸体供肾),这些受者在移植后6个月以上经活检诊断为CN。复发性FSGS或与其他肾小球病相关的FSGS患者被排除在外。87名患有CN的患者(30%)存在FSGS。FSGS在以下几组患者中更常见:年轻患者(P = 0.04)、黑人患者(P = 0.02)以及血清胆固醇水平升高(P = 0.002)和/或重度蛋白尿患者(P < 0.0001,均为单因素分析)。与无FSGS的CN相比,FSGS在移植后诊断时间更晚(P < 0.0001),并且FSGS与活检标本中的小动脉玻璃样变的存在相关(P = 0.04)。与无FSGS的CN相比,FSGS与死亡截尾的移植肾存活显著更差相关(P = 0.008,单因素Cox分析)。此外,当我们分析所有患有CN的患者时,通过多因素分析移植肾存活与以下参数相关:诊断时的血清肌酐水平(P < 0.0001)和蛋白尿(P = 0.004)、FSGS的存在(P = 0.03)以及间质纤维化和肾小管萎缩程度(CN评分;P < 0.0001,Cox分析)。有趣的是,使用降脂药物也与患有CN的患者移植肾存活改善相关(P = 0.0002,单因素Cox分析),尽管接受这些药物治疗的患者总血脂水平并无显著降低。总之,新生FSGS在移植后出现较晚且与小动脉玻璃样变相关,提示这些病变可能与慢性环孢素毒性有关。在CN中,FSGS的存在和间质纤维化的严重程度是移植肾存活的负性独立预测因素。降脂药物与移植肾存活之间可能的关系显然需要在未来的研究中仔细研究。